Roche drug hits endpoint in late-stage RA trial

Roche is announcing positive data from the first of five late-stage trials of Actemra as a therapy for rheumatoid arthritis. The trial of moderate to severe RA among patients who had inadequately responded to methotrexate hit its primary endpoint of significant improvement in disease signs and symptoms at week 24. "We are pleased that this study confirms the favorable efficacy and safety profile of Actemra in the treatment of RA. Actemra, through its unique blockade of the interleukin-6 receptor, will provide a new treatment option for people afflicted by rheumatoid arthritis," says William Burns, head of Roche Pharmaceuticals. Four more late-stage trials will report data this year.

- check out the release on the data
- here's the AFX report on Roche

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.